529 related articles for article (PubMed ID: 35078972)
1. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
2. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
[TBL] [Abstract][Full Text] [Related]
3. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
Wang L; Song J; Xiao X; Li D; Liu T; He X
J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
5. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
6. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM
Blood Adv; 2024 Jan; 8(2):429-440. PubMed ID: 37871309
[TBL] [Abstract][Full Text] [Related]
7. Molecular remission and response patterns in patients with mutant-
Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
[TBL] [Abstract][Full Text] [Related]
9. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
[TBL] [Abstract][Full Text] [Related]
10. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
11. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
12. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with
Weng GY; You WW; Liu HX; Cai Y; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1333-1339. PubMed ID: 37846681
[TBL] [Abstract][Full Text] [Related]
14. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Pollyea DA; Tallman MS; de Botton S; Kantarjian HM; Collins R; Stein AS; Frattini MG; Xu Q; Tosolini A; See WL; MacBeth KJ; Agresta SV; Attar EC; DiNardo CD; Stein EM
Leukemia; 2019 Nov; 33(11):2575-2584. PubMed ID: 30967620
[TBL] [Abstract][Full Text] [Related]
15. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
[TBL] [Abstract][Full Text] [Related]
17. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
18. Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.
Largeaud L; Bérard E; Bertoli S; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; De Mas V; Huguet F; Delabesse E; Récher C
Leuk Res; 2019 Jun; 81():82-87. PubMed ID: 31055247
[TBL] [Abstract][Full Text] [Related]
19. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
de Botton S; Brandwein JM; Wei AH; Pigneux A; Quesnel B; Thomas X; Legrand O; Recher C; Chantepie S; Hunault-Berger M; Boissel N; Nehme SA; Frattini MG; Tosolini A; Marion-Gallois R; Wang JJ; Cameron C; Siddiqui M; Hutton B; Milkovich G; Stein EM
Cancer Med; 2021 Sep; 10(18):6336-6343. PubMed ID: 34427990
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo CD; Venugopal S; Lachowiez C; Takahashi K; Loghavi S; Montalban-Bravo G; Wang X; Carraway H; Sekeres M; Sukkur A; Hammond D; Chien K; Maiti A; Masarova L; Sasaki K; Alvarado Y; Kadia T; Short NJ; Daver N; Borthakur G; Ravandi F; Kantarjian HM; Patel B; Dezern A; Roboz G; Garcia-Manero G
Blood Adv; 2023 Jun; 7(11):2378-2387. PubMed ID: 35973199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
